Collaboration agreement
VTT Technical Research Centre in Finland signed a two year contract with Bayer Schering Pharma AG to study the mode of action of a cancer drug developed by the German pharmaceutical company.
The work will use novel gene and cell biology methods developed by VTT. The contract furthers VTT's ambitions in expanding its competence in drug development. The organisation’s Medical Biotechnology unit has a programme that is identifying genes involved in prompting the formation of tumours, and another searching for drug compounds for preventing the growth and metastasis of breast and prostate cancer.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
